Impact of GLP-1 Agonist on Fat Tissue in Bariatric Surgery Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of GLP-1 agonists on adipose tissue in patients undergoing bariatric surgery. It aims to determine whether treatment with a GLP-1 analogue leads to significant changes in oxytocin levels compared to those not receiving the treatment. The research focuses on understanding how these treatments can help normalize weight gain and prevent metabolic syndrome symptoms. Participants will be monitored for their response to the GLP-1 treatment over a specified period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years of age.
* Patient able to read and understand the information/consent leaflet.
* Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40
* Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
* Membership of a social security scheme
* Patient's signed informed consent
* For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
* For non-GLP-1 analogue group: never taken GLP-1 analogues.

Exclusion Criteria:

* Pregnant or breast-feeding women.
* Vulnerable patients (under guardianship)
* Patients deprived of liberty

Where it's running

• CHU de Nice - Hôpital de l'Archet
  Nice, Alpes-maritimes, France Recruiting

Study contacts

• Principal investigator: Iannelli Antonio, PhD — Clinique Parc Impérial, Service de Chirurgie Digestive
• Study coordinator: ROUX Christian, PhD
• Email: roux.c@chu-nice.fr
• Phone: +3349209220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.